Juana Merino

Juana Merino

Auto-generated profile, based on publicly available information

Juana Merino

Department of Immunology, Clínica Universidad de Navarra, University of Navarra, Spain

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2017 in Journal of Immunological Methods
Verified
Journal Article
Closed access
JDJosé Antonio Delgado
José Antonio Delgado
Francisco Guillen-GrimaFrancisco Guillen-Grima
Francisco Guillen-Grima
CMCristina Moreno
Cristina Moreno
CPCarlos Panizo
Carlos Panizo
CPCarmen Pérez-Robles
Carmen Pérez-Robles
JMJuana Merino
Juana Merino

30 November 2009 in Haematologica
Verified
Journal Article
Closed access
PDF file
EDE. Domingo
E. Domingo
CMC. Moreno
C. Moreno
ASA. Sanchez-Ibarrola
A. Sanchez-Ibarrola
CPC. Panizo
C. Panizo
JPJosé A Páramo
José A Páramo
JMJ. Merino
J. Merino
In a recent paper by Béné and Kaeda,[1][1] technical approaches for minimal residual disease (MRD) assessment are extensively reviewed. PCR-based studies have proved to be 1-log more sensitive than flow cytometry (FC). For this reason, they are increasingly being preferred for MRD analysis,

11 April 2007 in Clinical and Experimental Immunology
Verified
Journal Article
Open access
PDF file
JMJ. Merino
J. Merino
NRN. Ramírez
N. Ramírez
CMC. Moreno
C. Moreno
ETEstefania Toledo
Estefania Toledo
MFM. Fernández
M. Fernández
ASA. Sánchez-Ibarrola
A. Sánchez-Ibarrola
CD160/BY55 is a glucosyl-phosphatidylinositol (GPI)-anchored cell membrane receptor that is expressed primarily in natural killer (NK) cells. Its presence in CD8+ T lymphocytes is considered to be a marker of cytotoxic activity, although there are few data in this regard. In the present work, we analysed the expression of CD160 in subpopulations of cytomegalovirus (CMV)-specific CD8+ T cells. Subpopulations were defined by CD28 and CD57 expression and exhibited varying degrees of differentiation and cytotoxic potential, as evaluated by the expression of perforin, interferon (IFN)-γ and interleukin (IL)-7Rα/CD127. We included subjects with different intensities of anti-viral immune response. Results showed that the terminally differentiated CD28– CD57+ subset displaying the highest level of perforin expressed CD160 at a level similar to that of memory CD28+ CD57–perforin– cells. A comparison of the expression of perforin in CD160+ cells versus CD160– cells showed that expression was significantly higher in the absence of CD160. Interestingly, the CMV-specific CD8+ T cell subset from a patient with ongoing CMV reactivation did not begin to express CD160 until day +92 of the follow-up period. Taken together, our data show that CD160 cannot be considered a cytotoxic marker in CMV-specific CD8+ T cells.